Squarepoint
IGMS

Squarepoint’s IGM Biosciences IGMS Stock Holding History

Squarepoint’s Portfolio IGMS Stock Details IGMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-26,312
Closed -$243K – 4003
2023
Q2 		$243K Buy
+26,312
New +$295K ﹤0.01% 3098
2022
Q2 		– Sell
-35,808
Closed -$957K – 3097
2022
Q1 		$957K Buy
35,808
+26,543
+286% +$494K ﹤0.01% 1615
2021
Q4 		$272K Buy
+9,265
New +$460K ﹤0.01% 2504
2021
Q2 		– Sell
-15,624
Closed -$1.2M – 3444
2021
Q1 		$1.2M Buy
15,624
+5,103
+49% +$464K 0.01% 1379
2020
Q4 		$929K Buy
10,521
+7,579
+258% +$533K 0.01% 1385
2020
Q3 		$217K Sell
2,942
-13,515
-82% -$800K ﹤0.01% 2036
2020
Q2 		$1.2M Buy
+16,457
New +$1,000K 0.02% 846
2020
Q1 		– Sell
-18,575
Closed -$709K – 2165
2019
Q4 		$709K Buy
+18,575
New +$467K ﹤0.01% 1553

Other funds holding IGMS

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Squarepoint's IGMS Position: Q3 2023 in Review

Squarepoint sold out of IGM Biosciences (IGMS) in Q3 2023, closing a stake of 26,312 shares — an estimated $243K sold.

Squarepoint first reported a position in IGMS in Q4 2019 and held it in 8 quarters. The position peaked at $1.2M in Q2 2020. 79 funds tracked by Wall St. Rank hold IGMS as of Q3 2023.

  • Squarepoint reported no remaining IGM Biosciences position as of Q3 2023 after selling out during the quarter.
  • Squarepoint sold 26,312 IGM Biosciences shares in Q3 2023, an estimated $243K.
  • Squarepoint first reported a position in IGM Biosciences in Q4 2019 and held it in 8 quarters.
  • Squarepoint's IGM Biosciences position peaked at $1.2M in Q2 2020.
  • 79 funds tracked by Wall St. Rank held IGM Biosciences as of Q3 2023.

Based on Squarepoint's 13F filing for Q3 2023, filed 14 Nov 2023.